在被华润三九并购控股两年后，昆药集团的高质量发展方向逐渐明晰：以"银发健康产业引领者"为目 标，开启二次创业新征程。 "昆药集团的战略转型，无异于第二次创业。"昆药集团总裁颜炜日前在接受中国证券报记者专访时表 示，公司正推进"融合+改革"双轮驱动，通过构建"昆药商道"体系、深化三七产业链布局、创新"产品 +服务"商业模式等举措，全力将公司打造为银发健康产业引领者。 昆药集团血塞通软胶囊生产车间 公司供图 深度融入华润医药体系 2023年，华润三九完成对昆药集团的并购控股。昆药集团这家历史悠久的老牌药企由此成为华润集团医 药板块的重要成员，掀开了创新发展的新篇章。 "昆药集团与华润三九的融合不是简单叠加，而是系统性重塑。"颜炜介绍，在融入华润三九后，昆药集 团制定了清晰的融合发展路线图：三年融合期完成价值、业务、组织、精神"四个重塑"；两年改革期推 进渠道深度变革；五年成长期实现高质量发展。目前公司已进入"模式再造与渠道体系深度变革"的关键 阶段。 在数字化建设方面，昆药集团充分借鉴了华润三九的成熟经验。记者了解到，在华润三九的数字化能力 赋能下，昆药集团已开发发货分析看板、纯销分析看板以及二级报表等数字化工具 ...

Core Viewpoint - Kunming Pharmaceutical Group aims to become a leader in the silver-haired health industry, marking a new entrepreneurial journey after being acquired by China Resources Sanjiu [1][2]. Group 1: Integration and Transformation - Following the acquisition, Kunming Pharmaceutical Group is undergoing a systematic restructuring, focusing on value, business, organization, and spirit over a three-year integration period [2]. - The company is transitioning its operational model from "experience-driven" to "data-driven" by leveraging digital tools developed with the support of China Resources Sanjiu [2][3]. - A significant channel reform is underway to consolidate its previously fragmented sales network, establishing a more centralized channel structure [3]. Group 2: Focus on Silver-Haired Health - The new management has prioritized focusing resources on the silver-haired health sector, moving away from previous scattered investments [4]. - The company has a strong foundation in natural medicine research, particularly in chronic disease management and elderly health [5]. - Kunming Pharmaceutical Group is implementing a dual-platform strategy focusing on chronic disease management and premium traditional Chinese medicine [5]. Group 3: Innovative Business Model - The company is developing a three-in-one model that combines pharmaceuticals, medical services, and emotional value, aiming to create a comprehensive health management ecosystem [6]. - Plans include the development of intelligent companionship devices that integrate medical data and AI to support elderly care [6]. Group 4: International Expansion - Kunming Pharmaceutical Group is actively pursuing international markets, particularly in traditional Chinese medicine, with a focus on plant-based medicines like Artemisinin and Sanqi [7]. - The company has submitted 90 overseas registration applications and has successfully registered 7 products, with its blood stasis remedy approved in 15 countries [7]. - The company aims to leverage its global network and expertise in Artemisinin to become a comprehensive international healthcare service provider [8].

Core Viewpoint - Kunming Pharmaceutical Group aims to become a leader in the silver-haired health industry, marking a new entrepreneurial journey after being acquired by China Resources Sanjiu [1][3] Group 1: Strategic Transformation - The company is undergoing a strategic transformation described as a "second entrepreneurship," focusing on a dual-driven approach of "integration + reform" [1][3] - A clear roadmap for integration has been established, with a three-year integration period to complete value, business, organization, and spirit restructuring [1][2] - The company is currently in a critical phase of "model reconstruction and deep channel transformation" [1] Group 2: Digitalization and Channel Integration - Kunming Pharmaceutical Group is leveraging China Resources Sanjiu's digital capabilities to shift its operational model from "experience-driven" to "data-driven" [2] - The company is reforming its sales channel system by integrating a previously fragmented network of distributors, establishing a more centralized channel structure [2] - The new channel system will focus resources on national brand building, laying a foundation for long-term development [2] Group 3: Research and Development Collaboration - The company is collaborating with multiple research institutions in the silver-haired health sector, combining strengths in resource integration and AI-assisted drug screening [2][3] - Joint research projects in traditional Chinese medicine are being explored, particularly in the field of specialty plant medicines [2] Group 4: Focus on Silver-Haired Health - The management has identified a need for greater focus in strategic planning, concentrating resources on the silver-haired health sector [3] - The company aims to leverage its historical expertise in natural medicine to enhance its offerings in chronic disease management and elderly health [3] Group 5: Innovative Business Model - An innovative business model combining "medicines + medical services + emotional value" is being developed to address the needs of the elderly [4] - The company plans to transition from a traditional pharmaceutical enterprise to a health management service provider, enhancing its research and digital capabilities [4] Group 6: International Expansion of Traditional Chinese Medicine - Kunming Pharmaceutical Group is actively pursuing international markets for traditional Chinese medicine, with a focus on plant-based medicines like artemisinin and Sanqi [5] - The company has submitted 90 overseas registration applications and successfully registered 7 products, with its blood stasis remedy approved in 15 countries [5] - The company aims to become a comprehensive international healthcare service provider, leveraging its global network and expertise in artemisinin products [5]

深耕国内毛驴养殖布局，强化全球原料资源把控力。加强科研体 系建设，落地与国内知名院校全方位合作，建立"1 院 3 中心"创新平 台；与部分"一带一路"国家，签订毛驴产业化发展项目合作备忘录， 构建全体系的驴皮国际供应链。 股票代码：000423 股票简称：东阿阿胶 东阿阿胶股份有限公司投资者关系活动记录表 编号：2025-05 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者 | □媒体采访 √业绩说明会 | | 关系活动类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | | 中金公司、中信证券、中信建投、浙商证券、国金证券、兴业证 | | 参与单位名称 | 券、东吴证券、开源证券、华泰证券、华福证券、国海证券、光大证 | | | 券、国投证券、以谦基金、子竹资本、行远自迩投资、才华资管、中 | | 及人员姓名 | 信保诚基金、麦星投资、国寿安保基金等券商分析师及广大投资者朋 | | 友 | | | 时间 | 2025 年 8 月 22 日 | | 地点 | 济南 | | | 董事、总裁 孙金妮 | | 上市公司 | 独立董事 文光伟 | | 接待人员姓 ...

Group 1 - The core event was the launch of the "National Medicine AI Avatar" system by the company, aimed at enhancing the quality development of traditional Chinese medicine (TCM) and accelerating its international expansion [2][5] - The company has established partnerships with multiple hospitals in Shenzhen and internet platforms like Xiaohongshu, focusing on integrating medical resources and improving patient services [2][3] - The company has signed cooperative agreements with two new medical alliance units, enhancing the distribution of quality medical resources to grassroots levels and addressing public healthcare challenges [3] Group 2 - The company has expanded its medical alliance network to over 20 top TCM universities and hospitals, further broadening its national collaboration footprint [3] - The acquisition of Shenzhen Tianyuan Traditional Chinese Medicine Hospital aims to strengthen the synergy between offline stores and online medical platforms [3] - The company is committed to an integrated development model of "medical education research," focusing on building specialized TCM departments and a full-time physician training system [3][6] Group 3 - The "National Medicine AI Avatar" system covers eight core TCM specialties, leveraging the clinical experience of ten renowned TCM experts [5] - The AI system allows for efficient patient information collection and analysis, enabling quicker online consultations [6] - The company has established a TCM inheritance workshop in Singapore to enhance overseas TCM service capabilities and has developed 16 clinical formulations that have been approved for use [6] Group 4 - The company has formed partnerships with platforms like Meituan, Douyin, and Gaode Map, creating a multi-channel ecosystem for TCM service dissemination [4] - The collaboration with Xiaohongshu allows the company to utilize content formats like notes and live broadcasts to educate users about TCM [4]

Core Viewpoint - The article highlights the strategic initiatives of the company in promoting traditional Chinese medicine and health products, focusing on product development, international expansion, and investment in the health industry [4][5][6]. Group 1: Product Development and Market Strategy - The company is committed to enhancing its flagship product, Pianzaihuang, and expanding its product line with significant items such as the compound Pianzaihuang lozenge and Yindan Pinggan capsules, continuously enriching its "big product" matrix [5]. - The cosmetics subsidiary has implemented a long-term incentive mechanism based on excess profit sharing, successfully launching several products that have achieved over 100 million in sales [5]. Group 2: International Expansion - The company actively participates in national-level events to promote the internationalization of traditional Chinese medicine, including the "Belt and Road" conference and various international trade expos scheduled for 2025 [5]. - The company is involved in multiple international trade fairs, enhancing its global presence and market reach [5]. Group 3: Investment in Health Industry - Since 2024, the company has established three funds, each with a scale of 1 billion, focusing on investments in traditional Chinese medicine, biomedicine, medical devices, and health-related industries [5]. - The company's equity stake in these funds ranges from 20% to 30%, indicating a strong commitment to the health sector [5]. Group 4: Research and Development - In 2024, the company is advancing clinical research on 11 projects related to Pianzaihuang and other traditional Chinese medicine products, laying the groundwork for expanding clinical applications [6]. - The company has a robust pipeline with 14 ongoing new drug projects, including two new traditional Chinese medicine drugs entering clinical trials [6]. - Recent advancements include the completion of Phase I clinical research for a chemical drug and the initiation of Phase II trials for another, showcasing the company's commitment to innovation [6].